Clinical trialNCT01830231UnknownPhase 2/PHASE3Interventional

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

SponsorAssociació per a la Recerca Oncologica, SpainEnrollment372Urothelium Transitional Cell Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Joaquim Bellmunt, MD/PhD
APRO
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Netherlands

Nki-Avl
Amsterdam, Amsterdam, Netherlands
Martijn Kerst, MD
Recruiting
Vumc Amsterdam
Amsterdam, Amsterdam, Netherlands
van den Eertwegh, MD
Not, yet, recruiting
St. Antoniusziekenhuis
Nieuwegein, Nieuwegein, Netherlands
Maartje Los, MD
Recruiting
Erasmus Mc Rotterdam
Rotterdam, Netherlands
Ronald De witt, MD, PHD
Recruiting

Spain

Centro Oncologico de Galica
A Coruña, A Coruña, Spain
Ana Medina, MD
Recruiting
Complejo Hospitalario Universitario A Coruña
A Coruña, A Coruña, Spain
Luis Miguel Antón Aparicio, MD
Recruiting
Hospital Clínico Universitario de Santiago
Santiago de Compostela, A Coruña, Spain
Urbano Anido
Recruiting
Hospital General Universitario de Elche
Elche, Alicante, Spain
Federico J. Vázquez
Recruiting
Hospital Vall D´hebron
Barcelona, Barcelona, Spain
Rafael Morales, MD
Recruiting
Hospital del Mar
Barcelona, Barcelona, Spain
Joaquim Bellmunt, MD, PhD
Recruiting
Hospital San Pedro de Alcántara
Cáceres, Cáceres, Spain
Ricardo Collado
Recruiting
Fundación Jiménez Díaz
Madrid, Madrid, Spain
Gustavo Rubio
Recruiting
Hospital Clínico San Carlos
Madrid, Madrid, Spain
José Luis González, MD
Not, yet, recruiting
Hospital Ramón Y Cajal
Madrid, Madrid, Spain
Enrique Grande, MD
Recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Daniel Castellano, MD
Not, yet, recruiting
Hospital Morales Meseguer
Murcia, Murcia, Spain
Enrique González
Recruiting
Clínica Universidad de Navarra
Pamplona, Navarre, Spain
Jose L. Pérez
Recruiting
Complejo Hospitalario Universitario Ourense. Hospital Santa María Nai
Ourense, Ourense, Spain
Ovidio Fernández, MD
Recruiting
Hospital Son Llatzer
Palma de Mallorca, Palma de Mallorca, Spain
Maria Belén González, MD
Recruiting
Hospital Lzoano Blesa
Zaragoza, Zaragoza, Spain
Eduardo Pujol, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cabazitaxel →Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)- →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2012
Primary completion: 30 Nov 2016
Completion: 30 Nov 2016
Last update posted: 28 Jan 2014
Registered enrollment: 372
Registry id: NCT01830231

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.